亲爱的研友该休息了!由于当前在线用户较少,发布求助请尽量完整地填写文献信息,科研通机器人24小时在线,伴您度过漫漫科研夜!身体可是革命的本钱,早点休息,好梦!

Efficacy and safety of maintenance and reliever combination budesonide–formoterol inhaler in patients with asthma at risk of severe exacerbations: a randomised controlled trial

医学 布地奈德 哮喘 福莫特罗 吸入器 养生 布地奈德/福莫特罗 计量吸入器 皮质类固醇 沙丁胺醇 随机对照试验 不利影响 恶化 物理疗法 内科学
作者
Mitesh Patel,Janine Pilcher,Alison Pritchard,Kyle Perrin,Justin Travers,Dominick E. Shaw,Shaun Holt,Matire L. N. Harwood,Peter Black,Mark Weatherall,Richard W. Beasley
出处
期刊:The Lancet Respiratory Medicine [Elsevier BV]
卷期号:1 (1): 32-42 被引量:221
标识
DOI:10.1016/s2213-2600(13)70007-9
摘要

Summary Background The Single combination budesonide–formoterol inhaler Maintenance And Reliever Therapy (SMART) regimen reduces severe asthma exacerbations in patients, but whether the high doses of corticosteroid and β agonist increase the risk of adverse effects with both short-term and cumulative exposure is not certain. Our aim was to investigate whether the SMART regimen would reduce the risk of overuse of β agonist, reduce the likelihood of patients to seek medical review when such episodes occurred, and if any reduction in severe asthma exacerbations would be at the cost of a higher burden of systemic corticosteroid. Methods In this 24-week trial undertaken at four primary health-care practices and one hospital in New Zealand, patients (aged 16–65 years) with a recent asthma exacerbation were randomly assigned in a 1:1 ratio to the SMART or standard fixed-dose regimen. Treatment in the SMART group consisted of two actuations of budesonide–formoterol (200 μg and 6 μg, respectively, per actuation) twice daily, delivered through a combination metered dose inhaler (MDI), with one extra actuation as needed for relief of symptoms; treatment in the standard group consisted of two actuations of budesonide–formoterol (200 μg and 6 μg, respectively, per actuation) twice daily through a combination MDI with one to two actuations of salbutamol (100 μg per actuation) by MDI as needed for relief of symptoms. MDIs were monitored electronically to measure actual use of medication. The allocation sequence for randomisation was computer generated, with a block size of eight per site. Participants, investigators, and the statistician were not masked to group assignment. The primary outcome was the proportion of participants with at least one high-use episode of β agonist (more than eight actuations per day of budesonide–formoterol in addition to the four maintenance doses in the SMART group or more than 16 actuations per day of salbutamol in the standard group). Analysis was by intention to treat. This trial is registered with the Australian New Zealand Clinical Trials Registry, number ACTRN12610000515099. Findings 303 patients were randomly assigned to the SMART (n=151) or standard group (n=152). No significant difference was noted between the SMART and standard groups in the proportion of participants with at least one high-use episode of β agonist (84 [56%] vs 68 [45%], respectively, relative risk 1·24 [95% CI 0·99–1·56]; p=0·058). There were fewer days of high use in the SMART group (mean 5·1 days [SD 14·3] vs 8·9 days [20·9], relative rate 0·58 [0·39–0·88]; p=0·01). Of the patients who had at least one high-use episode, those in the SMART group had fewer days of high use without medical review (8·5 days [17·8] vs 18·3 days [24·8], 0·49 [0·31–0·75]; p=0·001). The SMART regimen resulted in higher inhaled corticosteroid exposure (943·5 μg budesonide per day [1502·5] vs 684·3 μg budesonide per day [390·5], respectively; ratio of means 1·22 [1·06–1·41]; p=0·006), but reduced oral corticosteroid exposure (77·5 mg prednisone [240·5] vs 126·6 mg prednisone [382·1], respectively; p=0·011), with no significant difference in composite systemic corticosteroid exposure (793·7 mg prednisone equivalent per year [893·1] vs 772·1 mg prednisone equivalent per year [1062·7], respectively; 1·03 [0·86–1·22]; p=0·76). Participants in the SMART group had fewer severe asthma exacerbations (35 [weighted mean rate per year 0·53] vs 66 [0·97]; relative rate 0·54 [0·36–0·82]; p=0·004). Interpretation The SMART regimen has a favourable risk-to-benefit profile and can be recommended for use in adults at risk of severe asthma exacerbations. Funding Health Research Council of New Zealand.

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
hhuajw完成签到,获得积分10
5秒前
8秒前
领导范儿的应助被zhengjia采纳,获得10
11秒前
SUNny发布了新的文献求助10
13秒前
Maestro_S的应助被爱学习的doge采纳,获得10
14秒前
彭于晏的应助被爱学习的doge采纳,获得10
14秒前
星辰大海的应助被爱学习的doge采纳,获得10
14秒前
15秒前
今后的应助被爱学习的doge采纳,获得10
15秒前
酷波er的应助被爱学习的doge采纳,获得10
15秒前
15秒前
上官若男的应助被爱学习的doge采纳,获得10
21秒前
星辰大海的应助被爱学习的doge采纳,获得10
21秒前
爆米花的应助被爱学习的doge采纳,获得10
21秒前
FashionBoy的应助被爱学习的doge采纳,获得10
21秒前
bkagyin的应助被爱学习的doge采纳,获得10
21秒前
传奇3的应助被爱学习的doge采纳,获得30
21秒前
小马甲的应助被爱学习的doge采纳,获得10
21秒前
斯文败类的应助被爱学习的doge采纳,获得10
22秒前
汉堡包的应助被爱学习的doge采纳,获得10
22秒前
22秒前
25秒前
乐乐的应助被爱学习的doge采纳,获得10
28秒前
丘比特的应助被爱学习的doge采纳,获得10
28秒前
bkagyin的应助被爱学习的doge采纳,获得10
28秒前
Orange的应助被爱学习的doge采纳,获得10
28秒前
领导范儿的应助被爱学习的doge采纳,获得30
28秒前
我是老大的应助被爱学习的doge采纳,获得10
28秒前
情怀的应助被爱学习的doge采纳,获得10
28秒前
打打的应助被爱学习的doge采纳,获得10
28秒前
香蕉觅云的应助被爱学习的doge采纳,获得10
28秒前
传奇3的应助被爱学习的doge采纳,获得10
28秒前
29秒前
31秒前
32秒前
无语的新之完成签到,获得积分10
32秒前
32秒前
32秒前
33秒前
33秒前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
拉伸高分子熔体中缠结行为的模拟和小角中子散射研究 1700
The World Atlas of Wine 9th edition 1000
奈特基础组织学:配套组织病理学(第4版)(Netter's Essential Histology With Correlated Histopathology) 800
John McDowells Bildungstheorie 800
Social Psychology in the Real World 600
八旗制度の研究 600
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 计算机科学 工程类 有机化学 化学工程 生物化学 物理 复合材料 内科学 催化作用 光电子学 人工智能 细胞生物学 无机化学 物理化学 数学
热门帖子
关注 科研通微信公众号,转发送积分 8179936
求助须知:如何正确求助?哪些是违规求助? 9570159
关于积分的说明 21808414
捐赠科研通 7775767
什么是DOI,文献DOI怎么找? 3433224
关于科研通互助平台的介绍 2557347
邀请新用户注册赠送积分活动 2478929